苏金单抗治疗活动性类风湿关节炎的III期随机双盲研究
该III期研究纳入551例对TNF抑制剂应答不足或不耐受的活动性RA患者,随机接受苏金单抗150mg、75mg、阿巴西普或安慰剂。第24周时,苏金单抗150mg组ACR20应答率显著高于安慰剂(30.7% vs 18.1%,P=0.0305),75mg组未达显著(28.3%,P=0.0916),阿巴西普组为42.8%。苏金单抗150mg组DAS28-CRP改善显著,但HAQ DI和ACR50改善不显著;安全性各组相似。
要点
- 苏金单抗150mg组ACR20应答率显著优于安慰剂(30.7% vs 18.1%,P=0.0305)。
- 苏金单抗75mg组ACR20与安慰剂差异未达统计学显著(28.3%,P=0.0916)。
- 阿巴西普组ACR20应答率数值上高于苏金单抗组(42.8%)。
核心结论
- 苏金单抗150mg可改善对TNF抑制剂应答不足的活动性RA患者的体征、症状及疾病活动度。
- 阿巴西普观察到的改善在数值上高于苏金单抗。
- 本研究未发现苏金单抗新的或非预期安全性信号。
研究设计与样本
- III期随机、双盲、阳性对照及安慰剂对照研究。
- 551例活动性RA患者按1:1:1:1随机分组。
- 苏金单抗静脉10mg/kg(基线及第2、4周)后皮下150mg或75mg每4周,或阿巴西普或安慰剂同 schedule。
- 主要终点为第24周ACR20应答率(苏金单抗150mg或75mg vs 安慰剂)。
主要发现
- 第24周ACR20应答率:苏金单抗150mg组30.7%(P=0.0305),75mg组28.3%(P=0.0916),阿巴西普组42.8%,安慰剂组18.1%。
- 苏金单抗150mg组DAS28-CRP较基线显著下降(P=0.0495),75mg组不显著。
- 苏金单抗两剂量组HAQ DI改善及ACR50应答率与安慰剂相比均不显著。
- 总体安全性特征在各治疗组间相似。
临床怎么用
- 对于TNF抑制剂应答不足或不耐受的活动性RA患者,苏金单抗150mg可作为治疗选择之一。
- 苏金单抗75mg在本研究中未显示显著优于安慰剂的ACR20应答。
- 阿巴西普在本研究中的ACR20应答数值上高于苏金单抗,选择时需结合患者具体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to or intolerance of tumor necrosis factor (TNF) inhibitors. METHODS: In this phase III study, 551 patients were randomized (1:1:1:1) to receive intravenous secukinumab at a dose of 10 mg/kg (at baseline and weeks 2 and 4) followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks or, alternatively, abatacept or placebo on the same dosing schedule. The primary end point was the proportion of patients achieving 20% improvement in disease activity according to the American College of Rheumatology response criteria (ACR20) at week 24 in the secukinumab 150 mg or 75 mg treatment groups as compared with placebo. Key secondary end points included change from baseline to week 24 in the Disease Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) and the Health Assessment Questionnaire disability index (HAQ DI), as well as the ACR 50% improvement (ACR50) response rate at week 24. RESULTS: The primary efficacy end point was met in patients receiving 150 mg secukinumab, in whom the ACR20 response rate at week 24 was significantly higher than that in the placebo group. The ACR20 response rates at week 24 were 30.7% in patients receiving 150 mg secukinumab (P = 0.0305), 28.3% in those receiving 75 mg secukinumab (P = 0.0916), and 42.8% in those receiving abatacept, compared with 18.1% in the placebo group. A significant reduction in the DAS28-CRP was seen in patients treated with 150 mg secukinumab (P = 0.0495), but not in patients treated with 75 mg secukinumab. Improvements in the HAQ DI and ACR50 response rates were not significant in the 2 secukinumab dose groups compared with the placebo group. The overall safety profile was similar across all treatment groups. CONCLUSION: Secukinumab at a dose of 150 mg resulted in improvement in signs and symptoms and reduced disease activity in patients with active RA who had an inadequate response to TNF inhibitors. Improvements observed with abatacept were numerically higher than with secukinumab. There were no new or unexpected safety signals with secukinumab in this study.
引用
- Blanco FJ, Möricke R, Dokoupilova E, et al. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. Arthritis Rheumatol. 2017. PMID: 28217871. doi:10.1002/art.40070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。